| Sofinnova–Apollo Global Management: investment, 202205– commitment of up to $1b managed capital to Sofinnova Partners investment funds by Apollo |
2022-05-16 |
| BLIRT–Qiagen: investment, 202205 acquisition 96% ownership stake by Qiagen |
2022-05-11 |
| Biohaven Pharmaceuticals–Pfizer: investment, 202205– acquisition $11.6b in cash at $148.5/share excluding non-CGRP pipeline ANNOUNCED |
2022-05-10 |
| Domain Therapeutics–SEVERAL: investment, 202205 financing round Series A €39m co-led by Panacea Venture + CTI Life Sciences + 3B Future Health Fund |
2022-05-10 |
| Sidekick Health–SEVERAL: investment, 202205 financing round Series B $55m led by Novator Ventures |
2022-05-05 |
| Engimmune Therapeutics–SEVERAL: investment, 202205 seed financing round CHF15.5m co-led by Pureos Bioventures + Novo Seeds |
2022-05-03 |
| Tubulis–SEVERAL: investment, 202205 financing round Series B €60m led by new investor Andera Partners |
2022-05-03 |
| Bionter–Dynamk Capital: investment, 202204 Series Seed financing $3m from Dynamk Capital |
2022-04-27 |
| Boehringer–Roivant: AI-based drug discovery, 202204– collab research €na with VantAI using AI/ML to identify protein degraders |
2022-04-20 |
| CDR-Life–SEVERAL: investment, 202204 financing round Series A $76m co-led by Jeito Capital + RA Capital |
2022-04-13 |
| Cimeio Therapeutics–Versant Ventures: investment, 202204– Series A $50m commitment at launch from Versant Ventures |
2022-04-13 |
| Avi Medical–SEVERAL: investment, 202204 financing round Series B €50m led by Balderton Capital |
2022-04-06 |
| IonSense–Bruker: investment, 202204 acquisition of IonSense by Bruker |
2022-04-06 |
| Regeneron–ViGeneron: gene therapy, 202204– collab + option agreem to develop vgAAV-based therapeutics for one inherited retinal disease target |
2022-04-06 |
| Merck (DE)–Lonza: MAST platform, 202204 acquisiton €na of MAST automated bioreactor sampling system by Merk Life Science from Lonza |
2022-04-05 |
| Boehringer–Celeris Therapeutics: targeted protein degraders, 202204– collab AI-based drug discovery for target of Boehringer |
2022-04-04 |
| Labster–SEVERAL: investment, 202204 financing round Series C 2nd tranche $47m bringing total Series C to $107m |
2022-04-04 |
| Ebenbuild–SEVERAL: investment, 202203 seed financing round €2.5m co-led by HTGF + Bayern Kapital with business angels |
2022-03-31 |
| Immunic–4SC: vidofludimus, 202103 settlement of remaining royalty obligations for IMU-838 for $17.25m with 50% in cash + 50% in Immunic common stock |
2022-03-31 |
| Asahi Kasei–VectivBio: apraglutide, 202203– excl license $30m upfront + $170m milestones + royalties for developm + marketing in Japan |
2022-03-30 |
| Neuron23–SEVERAL: investment, 202203 financing round Series C $100m led by SoftBank Vision Fund 2 |
2022-03-30 |
| Sanofi–IGM Biosciences: IgM antibody agonists, 202203– collab RnD + commerc ww excl $150m upfront + >$6b milestones for cancer + inflammation |
2022-03-29 |
| Innovacell–EU (govt): credit, 202203– venture debt loan of up to €15m from EIB to Innovacell AG |
2022-03-24 |
| Affini-T Therapeutics–SEVERAL: investment, 202203 financing round $175m co-led by Vida Ventures + Leaps by Bayer |
2022-03-22 |
| Nucleai MD–SEVERAL: investment, 202203 financing round Series B $33m co-led by Section 32 + Sanofi Ventures |
2022-03-22 |
| BigOmics–Eppendorf: investment, 202203 investment from Eppendorf Innovation Company (EpIC) closes pre-Series A round |
2022-03-17 |
| Gilde Investment–SEVERAL: investment, 202203 first + final close of €517m Gilde Healthcare Private Equity IV fund |
2022-03-16 |
| Precirix–SEVERAL: investment, 202203 financing round Series B €80 co-led by new investors Inkef Capital + Jeito Capital + Forbion |
2022-03-16 |
| BMS–Temedica: digital companion diagnostic, 202203– collab development digital companion diagnostic for psoriasis patients |
2022-03-15 |
| PrognomiQ–SEVERAL: investment, 202203 financing round $46m led by Bruker Corp |
2022-03-15 |
| Ayoxxa–SEVERAL: investment, 202203– financing round providing runway for 3-5 years led by new investor Prosnav Capital NOT REALISED |
2022-03-14 |
| FGen–Ginkgo Bioworks: investment, 202203– acquisition of FGen AG by Ginkgo Bioworks for upfront payment + milestones ANNOUNCED |
2022-03-14 |
| Merck (DE)–Celeris Therapeutics: AI-based drug discovery, 202202– collab research small molecule binders + bifunctional degraders |
2022-03-09 |
| Eurazeo–SEVERAL: investment, 202203 first closing €160m of Kurma Partners Growth Opportunities Fund targeting €250m |
2022-03-07 |
| Proteona–Singleron: investment, 202203 acquisition of Proteona Pte Ltd by Singleron Biotechnologies |
2022-03-07 |
| ArrePath–SEVERAL: investment, 202203 seed financing round $20m co-led by BIVF + Insight Partners + Innospark Ventures |
2022-03-03 |
| Epsilogen–SEVERAL: investment, 202203 financing round Series B £30.75m led by new investor Novartis Venture Fund |
2022-03-02 |
| BioEcho–Ampersand: investment, 202203 minority growth equity investment €na from Ampersand Capital Partners |
2022-03-01 |
| In Ovo–SEVERAL: investment, 202203 financing round €34m with ECBF + ABN AMRO et al |
2022-03-01 |
| Heidelberg Pharma–SEVERAL: investment, 202202–202208 capital increase €79.91m with €76.24m thereof from Huadong Medicine reaching 25% shareholding |
2022-02-27 |
| Kumovis–3D Systems: investment, 202202– acquisition of Kumovis by 3D Systems |
2022-02-23 |
| Centauri Therapeutics–SEVERAL: investment, 202202 financing round Series A £24m with BIVF + Evotec + Novo REPAIR Impact Fund et al |
2022-02-16 |
| XO Life–SEVERAL: investment, 202202 financing round more than €2m from SeedLink + MediVentures + Aescuvest et al |
2022-02-16 |
| c-LEcta–Kerry Group: investment, 202202 acquisition 92% for €137m with management to retain balance of shares |
2022-02-15 |
| IMIDomics–Evotec: investment, 202202 strategic equity investment €na by Evotec |
2022-02-15 |
| NMD Pharma–SEVERAL: investment, 202202 financing round €35m led by new investor Jeito Capital + incl existing investors |
2022-02-15 |
| Green Elephant Biotech–SEVERAL: investment, 202201 pre-seed financing round mid-6-digit € led by BMH with business angels |
2022-02-11 |
| Haya Therapeutics–SEVERAL: investment, 202202 seed financing round extension $5m led by new investor Humboldt Fund |
2022-02-09 |
| Lindis Blood Care–SEVERAL: investment, 202202 follow-on financing round led by HTGF + Brandenburg Kapital + several private investors |
2022-02-09 |
| Formo–BRAIN Biotech: genome editing technology, 202202– collab using CRISPR BEC platform to scale production of bioidentical milk protein |
2022-02-08 |
| In-Part–Inova Software: investment, 202202 acquisition of In-Part by Inova |
2022-02-08 |
| Nemis Technologies–SEVERAL: investment, 202202 financing round Series A CHF7.75m from institutional + private investors |
2022-02-03 |
| Ethris–SEVERAL: investment, 202201 financing round Series B €23.3m led by Laureus Capital |
2022-02-01 |
| Glycotope–Canton Biologics: investment, 202201 acquisition of newly formed FyoniBio GmbH from Glycotope by CantonBio Deutschland GmbH |
2022-02-01 |
| myPOLS Biotec–Medix Biochemica: investment, 202202 acquisition 100% of myPOLS Biotec GmbH by Medix Biochemica |
2022-02-01 |
| Noventi–Temedica: healthcare data analytics, 202202– collab using Permea system to advance healthcare research with real-world data |
2022-02-01 |
| Zetta Genomics–SEVERAL: investment, 202202 seed financing round £2.5m with Cambridge Enterprise + Apex Ventures + Nina Capital |
2022-02-01 |
| Gandeeva Therapeutics–SEVERAL: investment, 202201 financing round Series A $40m led by Lux Capital + Leaps by Bayer |
2022-01-31 |
| Ribbon Biolabs–SEVERAL: investment, 202201 financing round Series A €18m led by Hadean Ventures |
2022-01-31 |
| xbird–Glooko: investment, 202201 acquisition of xbird GmbH by Glooko Inc |
2022-01-31 |
| Mainz Biomed–SEVERAL: investment, 202201 public follow-on offering $22.5m+$3.375m with 1.725m+225k common shares at $15/share |
2022-01-28 |
| Cellino–SEVERAL: investment, 202201 financing round Series A $80m led by Leaps by Bayer + 8VC + Humboldt Fund |
2022-01-25 |
| Cytovation–SEVERAL: investment, 202201 financing round Series A NOK180m (€20m) led by Sandwater + Canica |
2022-01-25 |
| InstaDeep–BioNTech: investment, 202201 financing round Series B totalling $100m incl co-investor BioNTech |
2022-01-25 |
| InstaDeep–SEVERAL: investment, 202201 financing round Series B $100m led by Alpha Intelligence Capital with CDIB |
2022-01-25 |
| Metagenomi–SEVERAL: investment, 202201 financing round Series B $175m co-led by PFM Health Sciences + Farallon Capital Mgt + NN |
2022-01-25 |
| Lift BioSciences–SEVERAL: investment, 202201 financing round £5m led by new investor Starbloom Capital |
2022-01-21 |
| Alterome Therapeutics–SEVERAL: investment, 202201 financing round Series A $64m led by OrbiMed |
2022-01-19 |
| Prolab Instruments–Bruker: investment, 202201 acquisition €na of Prolab Instruments Gmbh by Bruker |
2022-01-19 |
| Zogenix–UCB: investment, 202201– cash tender offer $1.76b at $26/share plus $135.7m CVR milestones ANNOUNCED |
2022-01-19 |
| Labiotech.eu–Inova Software: investment, 202201 acquisition by Inova |
2022-01-18 |
| PreOmics–Bruker: investment, 202201 Series B investment €13.5m from Bruker tog w secondary transaction making Bruker majority shareholder |
2022-01-18 |
| Indivumed–EU (govt): grant, 202201– funding €4.3m from ERDF Structural Fund REACT-EU programme for personalised cancer drug development |
2022-01-17 |
| Biosyntia–Wacker: biotin, 202201–collab developm of large-scale biotin production process based on sustainable fermentation |
2022-01-11 |
| Pantherna Therapeutics–SEVERAL: investment, 202201 follow-on financing round €4m led by existing investors Detlev Riesner + HTGF |
2022-01-11 |
| Thermo Fisher–JPMorgan Chase: investor conference, 202201 supply service Thermo Fisher presents at JP Morgan Healthcare Conference 2022 |
2022-01-11 |
| BioNTech–Crescendo Biologics: antibody technology, 202201–202512 collab ww up to $790m + royalties using Humabody VH platform for BioNTech targets |
2022-01-10 |
| Bruker–JPMorgan Chase: investor conference, 202201 supply service Bruker presents at JP Morgan Healthcare Conference 2022 |
2022-01-10 |
| Exelead–Merck (DE): investment, 202201 acquisition $760m in cash by Merck |
2022-01-06 |
| Pfizer–BioNTech: mRNA-based vaccines, 202201– collab developm $50m net cash upfront shingles vaccine with shared development cost + profits |
2022-01-05 |
| ALS Automated Lab Solutions–Sartorius: investment, 202201–2026 acquisition of 62.5% share in ALS with remaining share to be acquired in 2026 |
2022-01-03 |
| Evolva–Nice & Green: credit, 202112–202312 convertible notes financing with incremental lines up to max of CHF12m principal amount |
2021-12-27 |
| Grand Pharma–ITM: radiopharmaceutical, 202112– license excl dev + production + commerc of ITM-11 + ITM-41 + TOCscan in Greater China |
2021-12-27 |
| Gyroscope Therapeutics–Novartis: investment, 202112– acquisition $800m upfront + $700m milestones by Novartis ANNOUNCED |
2021-12-22 |
| Thuja Capital–SEVERAL: investment, 202112 final closing of Thuja Capital Heathcare Fund III at €76m incl investor EIF |
2021-12-21 |
| Roche–CombiGene: GC01 epilepsy gene therapy, 202110–202310 collab + excl ww license to Spark Tx $8.5m pfront + $320m milestones TERMINATED 10/23 |
2021-12-19 |
| Anaveon–SEVERAL: investment, 202112 financing round Series B CHF110m with new + lead investor Forbion |
2021-12-16 |
| Brainomix–SEVERAL: investment, 202112 financing round Series B £16m co-led by existing investors BIVF + Parkwalk Advisors |
2021-12-16 |
| Evotec–Gates Foundation: grant, 202112– grant $18m for drug r+d in area of women’s health + contraceptive technology |
2021-12-16 |
| Lonza–Agilent: analytical instruments, 202112– strategic alliance to integrate analytical technologies in Cocoon cell therapy production platform |
2021-12-15 |
| BMS–Immatics: TCR Bispecific, 202112– license ww excl $150m upfront + $770m milestones + royalties to IMA401 programme |
2021-12-14 |
| Novartis–Molecular Partners: DARPins, 202112– collab $20m upfront + $560m milestones + royalties license to develop + manuf + commerc DARPin-RLTs |
2021-12-14 |
| Vifor Pharma–CSL: investment, 202112– cash tender offer CHF10.9b ($11.7b) at CHF167/share ANNOUNCED |
2021-12-14 |
| Memo Therapeutics–Switzerland (govt): grant, 202112– FOPH grant CHF10.5m for clinical developm of SARS-CoV-2 antibody COVAB 36 |
2021-12-13 |
| deepCDR Biologics–Alloy Therapeutics: investment, 202112 acquisition of deepCDR Biologics by Alloy |
2021-12-09 |
| Forbion European Acquisition Corporation–SEVERAL: investment, 202112 SPAC US IPO $110m with 11m units at $10/unit |
2021-12-09 |
| Aleph Farms–Wacker: cell culture media, 202112– collab developm production process for growth-medium proteins for cultured meat |
2021-12-08 |
| Merck (DE)–Merck (DE): investment, 202112 third increase of financial commitment by €600m in evergreen corporate venture fund M Ventures |
2021-12-08 |
| Emergence Therapeutics–SEVERAL: investment, 202112 financing round Series A €87m led by Pontifax Venture Capital |
2021-12-07 |
| Freenome–SEVERAL: investment, 202112 financing round Series D $300m co-led by Perceptive Advisors + RA Capital Management |
2021-12-07 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
